124680-50-8

Usage

Molecular structure

The compound has a pyrimido-1,5,3-dioxazepine skeleton, which is a fused ring system consisting of a pyrimidine ring and a dioxazepine ring.

Substituents

The compound contains a 2,3-dihydro-3-phenylmethoxy-8-methyl group, which is a specific arrangement of atoms that can influence the compound's properties and reactivity.

Configuration

The compound has a (2R,3R,5R) configuration, which refers to the stereochemistry of the molecule. This means that the chiral centers at the 2nd, 3rd, and 5th positions have specific spatial arrangements (right-handed) that can affect the compound's biological activity and interactions with other molecules.

Biological activity

The compound may have potential biological activities or pharmacological uses due to its unique structure and configuration. However, further research and testing are needed to determine its specific properties and potential applications.

Complexity

The compound is a complex organic molecule with multiple functional groups and chiral centers, which can contribute to its potential applications in various fields, such as medicine, agriculture, or materials science.

Further research needed

The compound's properties and potential applications are not yet fully understood, and additional studies are required to explore its potential uses and to develop new methods for its synthesis and characterization.

Upstream product

• 50-89-5 thymidine 
• 14470-28-1 mono-4-methoxytrityl chloride 
• 42926-80-7 5'-O-(4-monomethoxytrityl)-2'-deoxythymidine 
• 130446-03-6 methanesulfonic acid (2R,3S,5R)-2-[bis(4-methoxyphenyl)phenylmethoxymethyl]-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)tetrahydrofuran-3-yl ester 

Downstream Products

• 177084-36-5 Hexadecanoic acid 2-{[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethoxy]-[2-(4-nitro-phenyl)-ethoxy]-phosphoryloxy}-1-hexadecanoyloxymethyl-ethyl ester 
• 177084-37-6 Tetradecanoic acid 2-{[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethoxy]-[2-(4-nitro-phenyl)-ethoxy]-phosphoryloxy}-1-tetradecanoyloxymethyl-ethyl ester 
• 177084-38-7 Phosphoric acid (2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethyl ester 2,3-bis-hexadecyloxy-propyl ester 2-(4-nitro-phenyl)-ethyl ester 
• 30516-87-1 3'-azido-2',3'-deoxythymidine 
• 385388-88-5 3'-isothiocyanato-5'-O-(4-methoxyphenyl)-diphenylmethyl-3'-deoxythymidine 
• 211300-21-9 3'-amino-5'-O-(4-methoxyphenyl)-diphenylmethyl-3'-deoxythymidine 
• 152873-32-0 1-[(2R,3S,5R)-3-Hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethyl]-3-[(2S,3S,5R)-2-[(4-methoxy-phenyl)-diphenyl-methoxymethyl]-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-3-yl]-thiourea 
• 124680-51-9 (2R,4R,5R)-1-[5-[bis(4-methoxyphenyl)phenylmethoxymethyl]-4-hydroxytetrahydrofuran-2-yl]-5-methyl-1H-pyrimidine-2,4-dione 
• 152388-78-8 3'-azido-3'-deoxy-5'-O-monomethoxytritylthymidine 
• 339178-42-6 (2R,4R,5R)-1-[5-[bis(4-methoxyphenyl)phenylmethoxymethyl]-4-(tert-butyldiphenylsilanyloxy)tetrahydrofuran-2-yl]-5-methyl-1H-pyrimidine-2,4-dione 
• 339178-44-8 (2S,3R,5R)-3-(tert-butyldiphenylsilanyloxy)-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)tetrahydrofuran-2-carboxylic acid 
• 339178-45-9 (2S,3R,5R)-3-(tert-butyldiphenylsilanyloxy)-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)tetrahydrofuran-2-carboxylic acid methyl ester 
• 339178-43-7 (2R,4R,5R)-1-[4-(tert-butyldiphenylsilanyloxy)-5-hydroxymethyltetrahydrofuran-2-yl]-5-methyl-1H-pyrimidine-2,4-dione 
• 339178-34-6 (2R,3R,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-(phenylselenenyl)tetrahydrofuran-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Preparation of 4'-substituted thymidines by substitution of the thymidine 5'-esters.

tert-Butyl thymidylate 3 was prepared from thymidine 1 in six steps and 67% overall yield. When the lithium trianion of 3 (prepared by treatment of 3 with excess LDA and then excess tert-butyllithum) is reacted with electrophiles, trapping occurs stereoselectively from either the alpha- or beta-face depending on the electrophile (Scheme 1). Deuterioacetic acid in deuteriomethanol affords mainly the alpha-deuterated product (4a/4b = 2.4:1) while all other electrophiles, e.g., phenylselenenyl chloride, allyl bromide, and N-fluorobenzenesulfonimide (NFSI), give predominately (or completely) the products of attack from the beta-face (5bcd/4bcd = 3.7:1 to 100:0). The structures of the products were determined by coupling constant analysis of both the initial compounds and the diols 6bcd prepared by ester reduction and by formation of the acetonides 7bc. The methyl ester of the 3'-epimer of thymidylic acid 9 was also prepared from thymidine 1 in nine steps and 74% overall yield. When the lithium trianion of 9 (prepared by treatment of 9 with excess LDA and then excess tert-butyllithum) is reacted with electrophiles, trapping also occurs stereoselectively with attack on either the alpha- or beta-face depending on the electrophile (Scheme 2). Again, deuterioacetic acid in deuteriomethanol affords mainly the beta-deuterated product (11a/10a = 1.6:1) while all other electrophiles, e.g., phenylselenenyl chloride, methyl iodide, allyl bromide, and NFSI, gave predominately (or completely) the product of attack from the alpha-face (8.7:1 to 100: 0). Again, the structures of the products were determined by coupling constant analysis of both the initial compounds, and the diols 12b-e were prepared by reduction of the ester and by formation of the acetonides 13bcd. A rationale has been developed using molecular mechanics calculations to explain the diastereoselectivity that involves staggered axial attack on the sp(2) carbon opposite to the pseudoaxial alkoxy group in the most stable half-chair conformation of the enolates, as shown in Schemes 3-5.

Incorporation of positively charged deoxynucleic S-methylthiourea linkages into oligodeoxyribonucleotides

Oligodeoxyribonucleic acids (15- and 18-mers) containing both negatively charged phosphate and positively charged S-methyl thiourea internucleoside linkages (DNmt/DNA chimera) have been synthesized. DNA binding characteristics and nuclease resistance of DNmt/DNA chimera have been evaluated.

38. Nucleotides: Part XLVI. The synthesis of phospholipid conjugates of antivirally active nucleosides by the improved phosphoramidite methodology

The application of the improved phosphoramidite strategy for the synthesis of oligonucleotides using β-eliminating protecting groups to phospholipid chemistry offers the possibility to synthesize phospholipid conjugates of AZT (6) and cordycepin. The synthesis of 3′-azido-3′-deoxythymidine (6) was achieved by a new isolation procedure without chromatographic purification steps in an overall yield of 50%. Protected cordycepin (=3′-deoxyadenosine) derivatives, the N6,2′-bis[2-(4-nitrophenyl)ethoxycarbonyl]cordycepin (12) and the N6,5′-bis[2-(4-nitrophenyl)ethoxycarbonyl]cordycepin (13) were prepared by known methods and direct acylation of N6-[2-(4-nitrophenyl)ethoxycarbonyl]cordycepin (9), respectively. These protected nucleosides and the 3′-azido-3′-deoxythymidine (6) reacted with newly synthesized and properly characterized lipid-phosphoramidites 21-25, catalyzed by 1H-tetrazole, to the corresponding nucleoside-phospholipid conjugates 26-38 in high yield. The deprotection was accomplished via β-elimination with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in aprotic solvents to give analytically pure nucleoside-phospholipid diesters 39-51 as triethylammonium or sodium salts. The newly synthesized compounds were characterized by elemental analyses and UV and 1H-NMR spectra.